EXPERTISE
Principal areas of expertise: Experimental oncology; Pharmacology
WORK EXPERIENCE
From January 2017 to present
Employer: Istituto Superiore di Sanità (ISS) (Italian National Institute of Health)
Sector: Department of Oncology and Molecular Medicine (OMM)
Position held: Head of the Department
Main activities and responsibilities:
Direction of the department mainly dedicated to research on cancer, genetic disease and molecular mechanisms of diseases including about 140 persons (about 90 full time employees).
Member of the Committee for the authorization of phase 1 clinical trials (June 2020 – present, Decrees of the Ministry of Health June 30, 2020 and May 7, 2021).
Member, as permanent delegate of the ISS President, of the Prices and Reimbursement Committee of the Italian Drug Agency (AIFA) (October 2018 – present).
Member, as permanent delegate of the ISS President, of the Technical and Scientific Committee of the Italian Drug Agency (AIFA) (September 2015 – present).
Expert for the evaluation of authorization requests for phase 1 clinical trials.
Expert for the evaluation of non-clinical dossiers for marketing authorization under centralized procedure (EMA/AIFA).
From October 2004 to December 2016
Employer: Istituto Superiore di Sanità
Sector: Department of Hematology, Oncology and Molecular Medicine (EOMM)
Position held: Research director (Dirigente di ricerca)
Main activities and responsibilities:
Section head.
Responsible of the Cancer stem cell biobank.
Responsible of the Flow and Mass Cytometry facility of the EOMM Dept.
Expert for the evaluation of authorization requests for phase 1 clinical trials.
Expert for the evaluation of non-clinical dossiers for marketing authorization under centralized procedure (EMA/AIFA).
From June 1999 to September 2004
Employer: “G.B. Grassi” Hospital (ASL Roma D)
Sector: Clinical Pathology Section
Position held: Substantive consultant (Dirigente medico)
From 1999 to 2005
Employer: University of Rome “Tor Vergata”
Sector: Teaching
Position held: Contract professor
Main activities and responsibilities: Pharmacology
From June 1991 to March 1999
Employer: “Cesare Serono” Research Insitute
Sector: Discovery department
Position held: Project leader
Main activities and responsibilities: Immunology, Hematology
From August 1988 to May 1991
Employer: Corpo di Sanità Militare (Italian Army Medical Service)
Sector: Medicine / Legal Medicine
Position held: Medical Officer
EDUCATION AND TRAINING
1981–1987
Organization: “Sapienza” University of Rome
Principal subjects/skills: Medicine
Title of qualification: Medical Doctor
1987–1991
Organization: “Sapienza” University of Rome
Principal subjects/skills: School of Specialization in Pharmacology
Title of qualification: Specialist in Clinical Pharmacology
1999–2003
Organization: “Sapienza” University of Rome
Principal subjects/skills: School of Specialization in Clinical Pathology
Title of qualification: Specialist in Clinical Pathology
LANGUAGES
Mother tongue
Italian
Other languages
English – Reading: C1
English – Writing: B2
English – Verbal: B2
PUBBLICATIONS
1. Manic G, Musella M, Corradi F, Sistigu A, Vitale S, Soliman Abdel Rehim S, Mattiello L, Malacaria E, Galassi C, Signore M, Pallocca M, Scalera S, Goeman F, De Nicola F, Guarracino A, Pennisi R, Antonangeli F, Sperati F, Baiocchi M, Biffoni M, Fanciulli M, Maugeri-Saccà M, Franchitto A, Pichierri P, De Maria R, Vitale I. Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51. Cell Death Differ. 2021 Feb 2. doi: 10.1038/s41418-020-00733-4. Online ahead of print.
2. Romeo S, Zeni O, Sannino A, Lagorio S, Biffoni M, Scarfì MR. Genotoxicity of radiofrequency electromagnetic fields: Protocol for a systematic review of in vitro studies. Environ Int. 2021 Mar;148:106386. doi: 10.1016/j.envint.2021.106386. Epub 2021 Jan 21.
3. Abbonizio F, Hassan HJ, Santagostino E, Arcieri R, Biffoni M, Giampaolo A; Italian Association of Haemophilia Centres; Italian Association of Haemophilia Centres. Epidemiological data and treatment strategies in children with severe haemophilia in Italy. Ann Ist Super Sanita. 2020 Oct–Dec;56(4):437-443. doi: 10.4415/ANN_20_04_05.
4. Francescangeli F, De Angelis ML, Baiocchi M, Rossi R, Biffoni M, Zeuner A. COVID-19-Induced Modifications in the Tumor Microenvironment: Do They Affect Cancer Reawakening and Metastatic Relapse? Front Oncol. 2020 Oct 26;10:592891. doi: 10.3389/fonc.2020.592891. eCollection 2020.
5. Casado J, Lehtonen O, Rantanen V, Kaipio K, Pasquini L, Häkkinen A, Petrucci E, Hynninen J, Hietanen S, Carpén O, Biffoni M, Färkkilä A, Hautaniemi S. Agile Workflow For Interactive Analysis Of Mass Cytometry Data. Bioinformatics. 2020 Nov 2:btaa946. doi: 10.1093/bioinformatics/btaa946. Online ahead of print.
6. Palma A, Grande S, Ricci-Vitiani L, Luciani AM, Buccarelli M, Biffoni M, Dini V, Cirrone GAP, Ciocca M, Guidoni L, Pallini R, Viti V, Rosi A. Different Mechanisms Underlie the Metabolic Response of GBM Stem-Like Cells to Ionizing Radiation: Biological and MRS Studies on Effects of Photons and Carbon Ions. Int J Mol Sci. 2020 Jul 21;21(14):5167. doi: 10.3390/ijms21145167.
7. Häkkinen A, Koiranen J, Casado J, Kaipio K, Lehtonen O, Petrucci E, Hynninen J, Hietanen S, Carpén O, Pasquini L, Biffoni M, Lehtonen R, Hautaniemi S. qSNE: Quadratic rate t-SNE optimizer with automatic parameter tuning for large data sets. Bioinformatics. 2020 Jul 14:btaa637. doi: 10.1093/bioinformatics/btaa637. Epub ahead of print.
8. Buccarelli M, Lulli V, Giuliani A, Signore M, Martini M, D'Alessandris QG, Giannetti S, Novelli A, Ilari R, Giurato G, Boe A, Castellani G, Spartano S, Marangi G, Biffoni M, Genuardi M, Pallini R, Marziali G, Ricci-Vitiani L. Deregulated expression of the imprinted DLK1-DIO3 region in Glioblastoma Stem-like Cells: tumor suppressor role of lncRNA MEG3. Neuro Oncol. 2020 May 27:noaa127. doi: 10.1093/neuonc/noaa127. Epub ahead of print.
9. Lulli V, Buccarelli M, Ilari R, Castellani G, De Dominicis C, Di Giamberardino A, D'Alessandris QG, Giannetti S, Martini M, Stumpo V, Boe A, De Luca G, Biffoni M, Marziali G, Pallini R, Ricci-Vitiani L. Mir-370-3p Impairs Glioblastoma Stem-Like Cell Malignancy Regulating a Complex Interplay between HMGA2/HIF1A and the Oncogenic Long Non-Coding RNA (lncRNA) NEAT1. Int J Mol Sci. 2020 May 20;21(10):3610. doi: 10.3390/ijms21103610.
10. Macchia I, La Sorsa V, Ruspantini I, Sanchez M, Tirelli V, Carollo M, Fedele G, Leone P, Schiavoni G, Buccione C, Rizza P, Nisticò P, Palermo B, Morrone S, Stabile H, Rughetti A, Nuti M, Zizzari IG, Fionda C, Maggio R, Capuano C, Quintarelli C, Sinibaldi M, Agrati C, Casetti R, Rozo Gonzalez A, Iacobone F, Gismondi A, Belardelli F, Biffoni M, Urbani F. Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring. J Immunol Res. 2020 Apr 12;2020:1938704. doi: 10.1155/2020/1938704. Erratum in: J Immunol Res. 2020 Aug 10;2020:2698258.
11. Pedini F, De Luca G, Felicetti F, Puglisi R, Boe A, Arasi MB, Fratini F, Mattia G, Spada M, Caporali S, Biffoni M, Giuliani A, Carè A, Felli N. Joint action of miR-126 and MAPK/PI3K inhibitors against metastatic melanoma. Mol Oncol. 2019;13(9):1836-1854.
12. Castiello L, Sestili P, Schiavoni G, Dattilo R, Monque DM, Ciaffoni F, Iezzi M, Lamolinara A, Sistigu A, Moschella F, Pacca AM, Macchia D, Ferrantini M, Zeuner A, Biffoni M, Proietti E, Belardelli F, Aricò E. Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells. Cancer Immunol Res. 2018;6(6):658-670.
13. Grande S, Palma A, Ricci-Vitiani L, Luciani AM, Buccarelli M, Biffoni M, Molinari A, Calcabrini A, D'Amore E, Guidoni L, Pallini R, Viti V, Rosi A. Metabolic Heterogeneity Evidenced by MRS among Patient-Derived Glioblastoma Multiforme Stem-Like Cells Accounts for Cell Clustering and Different Responses to Drugs. Stem Cells Int. 2018 Feb 18;2018:3292704.
14. Sciuto MR, Warnken U, Schnölzer M, Valvo C, Brunetto L, Boe A, Biffoni M, Krammer PH, De Maria R, Haas TL. Two-Step Coimmunoprecipitation (TIP) Enables Efficient and Highly Selective Isolation of Native Protein Complexes. Mol Cell Proteomics. 2018 May;17(5):993-1009.
15. Haas TL, Sciuto MR, Brunetto L, Valvo C, Signore M, Fiori ME, di Martino S, Giannetti S, Morgante L, Boe A, Patrizii M, Warnken U, Schnölzer M, Ciolfi A, Di Stefano C, Biffoni M, Ricci-Vitiani L, Pallini R, De Maria R. Integrin α7 Is a Functional Marker and Potential Therapeutic Target in Glioblastoma. Cell Stem Cell. 2017 Jul 6;21(1):35-50.
16. Marziali G, Buccarelli M, Giuliani A, Ilari R, Grande S, Palma A, D'Alessandris QG, Martini M, Biffoni M, Pallini R, Ricci-Vitiani L. A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes. Mol Oncol. 2017 Mar 1. doi: 10.1002/1878-0261.12047. [Epub ahead of print]
17. D'Alessandris QG, Biffoni M, Martini M, Runci D, Buccarelli M, Cenci T, Signore M, Stancato L, Olivi A, De Maria R, Larocca LM, Ricci-Vitiani L, Pallini R. The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response. Neuro Oncol. 2017 Feb 13. doi: 10.1093/neuonc/now304. [Epub ahead of print].
18. Fiorenzano A, Pascale E, D'Aniello C, Acampora D, Bassalert C, Russo F, Andolfi G, Biffoni M, Francescangeli F, Zeuner A, Angelini C, Chazaud C, Patriarca EJ, Fico A, Minchiotti G. Cripto is essential to capture mouse epiblast stem cell and human embryonic stem cell pluripotency. Nat Commun. 2016 Sep 2;7:12589.
19. Coscia C, Parolini I, Sanchez M, Biffoni M, Boussadia Z, Zanetti C, Fiani ML, Sargiacomo M. Generation, Quantification, and Tracing of Metabolically Labeled Fluorescent Exosomes. Methods Mol Biol. 2016;1448:217-35. doi: 10.1007/978-1-4939-3753-0_16.
20. Signore M, Buccarelli M, Pilozzi E, De Luca G, Cappellari M, Fanciulli M, Goeman F, Melucci E, Biffoni M, Ricci-Vitiani L. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response. Oncotarget. 2016 Jun 6. doi: 10.18632/oncotarget.9859.
21. Buoncervello M, Romagnoli G, Buccarelli M, Fragale A, Toschi E, Parlato S, Lucchetti D, Macchia D, Spada M, Canini I, Sanchez M, Falchi M, Musella M, Biffoni M, Belardelli F, Capone I, Sgambato A, Ricci-Vitiani L, Gabriele L. IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer. Oncotarget. 2016 Mar 25. doi: 10.18632/oncotarget.8379.
22. Marziali G, Signore M, Buccarelli M, Grande S, Palma A, Biffoni M, Rosi A, D'Alessandris QG, Martini M, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L. Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome. Sci Rep. 2016 Feb 9;6:21557. doi: 10.1038/srep21557.
23. D'Ambrosio A, Cossu A, Amendola A, Zandri A, Butera A, Sanchez M, Biffoni M, Pronio A, Montesani C, Kohn A, Pica R, Boirivant M. Lamina Propria CD4+LAP+ Regulatory T Cells Are Increased in Active Ulcerative Colitis but Show Increased IL-17 Expression and Reduced Suppressor Activity. J Crohns Colitis. 2016 Mar;10(3):346-53. doi: 10.1093/ecco-jcc/jjv216. Epub 2015 Nov 20.
24. Lulli V, Buccarelli M, Martini M, Signore M, Biffoni M, Giannetti S, Morgante L, Marziali G, Ilari R, Pagliuca A, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L. miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal. Oncotarget. 2015 Nov 10;6(35):37241-56. doi: 10.18632/oncotarget.5925.
25. Dima M, Pecce V, Biffoni M, Di Gioia CR, Tallini G, Biffoni M, Rosignolo F, Verrienti A, Sponziello M, Damante G, Russo D, Durante C. Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers. Endocrine. 2016 Jul;53(1):145-56. doi: 10.1007/s12020-015-0739-y. Epub 2015 Sep 14.
26. Grasso F, Di Meo S, De Luca G, Pasquini L, Rossi S, Boirivant M, Biffoni M, Bignami M, Di Carlo E. The MUTYH base excision repair gene protects against inflammation-associated colorectal carcinogenesis. Oncotarget. 2015 Aug 14;6(23):19671-84.
27. Shytaj IL, Nickel G, Arts E, Farrell N, Biffoni M, Pal R, Chung HK, LaBranche C, Montefiori D, Vargas-Inchaustegui D, Robert-Guroff M, Lewis MG, Sacha JB, Palamara AT, Savarino A. Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection. J Virol. 2015 Aug;89(15):7521-35. doi: 10.1128/JVI.00396-15. Epub 2015 May 13.
28. Pecchia I, Dini V, Ricci-Vitiani L, Biffoni M, Balduzzi M, Fratini E, Belli M, Campa A, Esposito G, Cirrone G, Romano F, Stancampiano C, Pelacchi F, Pallini R, Tabocchini MA. Glioblastoma stem cells: radiobiological response to ionising radiations of different qualities. Radiat Prot Dosimetry. 2015 Sep;166(1-4):374-8. doi: 10.1093/rpd/ncv299. Epub 2015 May 11.
29. Rosi A, Ricci-Vitiani L, Biffoni M, Grande S, Luciani AM, Palma A, Runci D, Cappellari M, De Maria R, Guidoni L, Pallini R, Viti V. (1)H NMR spectroscopy of glioblastoma stem-like cells identifies alpha-aminoadipate as a marker of tumor aggressiveness. NMR Biomed. 2015 Mar;28(3):317-26.
30. Riccioni R, Lulli V, Castelli G, Biffoni M, Tiberio R, Pelosi E, Lo-Coco F, Testa U. miR-21 is overexpressed in NPM1-mutant acute myeloid leukemias. Leuk Res. 2015 Feb;39(2):221-8.
31. Zeuner A, Francescangeli F, Contavalli P, Zapparelli G, Apuzzo T, Eramo A, Baiocchi M, De Angelis ML, Biffoni M, Sette G, Todaro M, Stassi G, De Maria R. Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer. Cell Death Differ. 2014 Dec;21(12):1877-88.
32. Signore M, Pelacchi F, di Martino S, Runci D, Biffoni M, Giannetti S, Morgante L, De Majo M, Petricoin EF, Stancato L, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. Cell Death Dis. 2014 May 8;5:e1223.
33. Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S, Cocorullo G, Gulotta G, Dieli F, De Maria R, Stassi G. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014 Mar 6;14(3):342-56.
34. Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Benedetto AD, Todaro M, Stassi G, Sperati F, Amabile MI, Pilozzi E, Patrizii M, Biffoni M, Maugeri-Saccà M, Piccolo S, De Maria R. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene. 2015 Feb 5;34(6):681-90.
35. Fiori ME, Barbini C, Haas TL, Marroncelli N, Patrizii M, Biffoni M, De Maria R. Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell Death Differ. 2014 May;21(5):774-82.
36. Sette G, Fecchi K, Salvati V, Lotti F, Pilozzi E, Duranti E, Biffoni M, Pagliuca A, Martinetti D, Memeo L, Milella M, De Maria R, Eramo A. Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. J Exp Clin Cancer Res. 2013 Nov 16;32:91.
37. Guidoni L, Ricci-Vitiani L, Rosi A, Palma A, Grande S, Luciani AM, Pelacchi F, di Martino S, Colosimo C, Biffoni M, De Maria R, Pallini R, Viti V. 1H NMR detects different metabolic profiles in glioblastoma stem-like cells. NMR Biomed. 2014 Feb;27(2):129-45.
38. Todaro M, Turdo A, Bartucci M, Iovino F, Dattilo R, Biffoni M, Stassi G, Federici G, De Maria R, Zeuner A. Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy. Cancer Res. 2013 Nov 1;73(21):6393-400.
39. Gabellini C, De Luca T, Trisciuoglio D, Desideri M, Di Martile M, Passeri D, Candiloro A, Biffoni M, Rizzo MG, Orlandi A, Del Bufalo D. BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition. Carcinogenesis. 2013 Nov;34(11):2558-67.
40. Felli N, Felicetti F, Lustri AM, Errico MC, Bottero L, Cannistraci A, De Feo A, Petrini M, Pedini F, Biffoni M, Alvino E, Negrini M, Ferracin M, Mattia G, Carè A. miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PLoS One. 2013;8(2):e56824.
41. Pelosi E, Castelli G, Martin-Padura I, Bordoni V, Santoro S, Conigliaro A, Cerio AM, De Santis Puzzonia M, Marighetti P, Biffoni M, Alonzi T, Amicone L, Alcalay M, Bertolini F, Testa U, Tripodi M. Human haemato-endothelial precursors: cord blood CD34+ cells produce haemogenic endothelium. PLoS One. 2012;7(12):e51109.
42. Marcon F, Carotti D, Andreoli C, Siniscalchi E, Leopardi P, Caiola S, Biffoni M, Zijno A, Medda E, Nisticò L, Rossi S, Crebelli R. DNA damage response in monozygotic twins discordant for smoking habits. Mutagenesis. 2013 Mar;28(2):135-44.
43. Pagliuca A, Valvo C, Fabrizi E, di Martino S, Biffoni M, Runci D, Forte S, De Maria R, Ricci-Vitiani L. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene. 2013 Oct;32(40):4806-13.
44. Sette G, Salvati V, Memeo L, Fecchi K, Colarossi C, Di Matteo P, Signore M, Biffoni M, D'Andrea V, De Antoni E, Canzonieri V, De Maria R, Eramo A. EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential. PLoS One. 2012;7(10):e46891.
45. Francescangeli F, Patrizii M, Signore M, Federici G, Di Franco S, Pagliuca A, Baiocchi M, Biffoni M, Ricci Vitiani L, Todaro M, De Maria R, Zeuner A. Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. Stem Cells. 2012 Sep;30(9):1819-30.
46. Coppola V, Musumeci M, Patrizii M, Cannistraci A, Addario A, Maugeri-Saccà M, Biffoni M, Francescangeli F, Cordenonsi M, Piccolo S, Memeo L, Pagliuca A, Muto G, Zeuner A, De Maria R, Bonci D. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition. Oncogene. 2013 Apr 4;32(14):1843-53. doi: 10.1038/onc.2012.194. Epub 2012 May 21.
47. Petrucci E, Pasquini L, Bernabei M, Saulle E, Biffoni M, Accarpio F, Sibio S, Di Giorgio A, Di Donato V, Casorelli A, Benedetti-Panici P, Testa U. A small molecule SMAC mimic LBW242 potentiates TRAIL- and anticancer drug-mediated cell death of ovarian cancer cells. PLoS One. 2012;7(4):e35073. doi: 10.1371/journal.pone.0035073. Epub 2012 Apr 25. PubMed PMID: 22558117; PubMed Central PMCID: PMC3338831.2
48. Bartucci M, Svensson S, Romania P, Dattilo R, Patrizii M, Signore M, Navarra S, Lotti F, Biffoni M, Pilozzi E, Duranti E, Martinelli S, Rinaldo C, Zeuner A, Maugeri-Saccà M, Eramo A, De Maria R. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ. 2012 May;19(5):768-78. doi: 10.1038/cdd.2011.170. Epub 2011 Nov 25. PubMed PMID: 22117197; PubMed Central PMCID: PMC3321626.2
49. Bartucci M, Dattilo R, Martinetti D, Todaro M, Zapparelli G, Di Virgilio A, Biffoni M, De Maria R, Zeuner A. Prevention of chemotherapy-induced anemia and thrombocytopenia by constant administration of stem cell factor. Clin Cancer Res. 2011 Oct 1;17(19):6185-91.
50. Musumeci M, Coppola V, Addario A, Patrizii M, Maugeri-Saccà M, Memeo L, Colarossi C, Francescangeli F, Biffoni M, Collura D, Giacobbe A, D'Urso L, Falchi M, Venneri MA, Muto G, De Maria R, Bonci D. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene. 2011 Oct 13;30(41):4231-42.
51. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, De Maria R. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010 Dec 9;468(7325):824-8.
52. Pallini R, Ricci-Vitiani L, Montano N, Mollinari C, Biffoni M, Cenci T, Pierconti F, Martini M, De Maria R, Larocca LM. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer. 2011 Jan 1;117(1):162-74.
53. Bartucci M, Svensson S, Ricci-Vitiani L, Dattilo R, Biffoni M, Signore M, Ferla R, De Maria R, Surmacz E. Obesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fluorouracil in colorectal tumor stem cells. Endocr Relat Cancer. 2010 Aug 16;17(3):823-33.
54. Po A, Ferretti E, Miele E, De Smaele E, Paganelli A, Canettieri G, Coni S, Di Marcotullio L, Biffoni M, Massimi L, Di Rocco C, Screpanti I, Gulino A. Hedgehog controls neural stem cells through p53-independent regulation of Nanog. EMBO J. 2010 Aug 4;29(15):2646-58.
55. Ricci-Vitiani L, Mollinari C, di Martino S, Biffoni M, Pilozzi E, Pagliuca A, de Stefano MC, Circo R, Merlo D, De Maria R, Garaci E. Thymosin beta4 targeting impairs tumorigenic activity of colon cancer stem cells. FASEB J. 2010 Nov;24(11):4291-301.
56. Baiocchi M, Biffoni M, Ricci-Vitiani L, Pilozzi E, De Maria R. New models for cancer research: human cancer stem cell xenografts. Curr Opin Pharmacol. 2010 Aug;10(4):380-4.
57. Starnes LM, Sorrentino A, Pelosi E, Ballarino M, Morsilli O, Biffoni M, Santoro S, Felli N, Castelli G, De Marchis ML, Mastroberardino G, Gabbianelli M, Fatica A, Bozzoni I, Nervi C, Peschle C. NFI-A directs the fate of hematopoietic progenitors to the erythroid or granulocytic lineage and controls beta-globin and G-CSF receptor expression. Blood. 2009 Aug 27;114(9):1753-63. doi: 10.1182/blood-2008-12-196196. Epub 2009 Jun 19. PubMed PMID: 19542302.3
58. Felicetti F, Parolini I, Bottero L, Fecchi K, Errico MC, Raggi C, Biffoni M, Spadaro F, Lisanti MP, Sargiacomo M, Carè A. Caveolin-1 tumor-promoting role in human melanoma. Int J Cancer. 2009 Oct 1;125(7):1514-22.
59. Petronelli A, Saulle E, Pasquini L, Petrucci E, Mariani G, Biffoni M, Ferretti G, Scambia G, Benedetti-Panici P, Greggi S, Cognetti F, Russo MA, Sporn M, Testa U. High sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDO-Imidazolide. Cancer Lett. 2009 Sep 18;282(2):214-28.
60. Felli N, Pedini F, Romania P, Biffoni M, Morsilli O, Castelli G, Santoro S, Chicarella S, Sorrentino A, Peschle C, Marziali G. MicroRNA 223-dependent expression of LMO2 regulates normal erythropoiesis. Haematologica. 2009 Apr;94(4):479-86.
61. Romania P, Lulli V, Pelosi E, Biffoni M, Peschle C, Marziali G. MicroRNA 155 modulates megakaryopoiesis at progenitor and precursor level by targeting Ets-1 and Meis1 transcription factors. Br J Haematol. 2008 Nov;143(4):570-80. doi: 10.1111/j.1365-2141.2008.07382.x. PubMed PMID: 18950466.4
62. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C, Bartucci M, Muto G, Peschle C, De Maria R. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008 Nov;14(11):1271-7.
63. Labbaye C, Spinello I, Quaranta MT, Pelosi E, Pasquini L, Petrucci E, Biffoni M, Nuzzolo ER, Billi M, Foà R, Brunetti E, Grignani F, Testa U, Peschle C. A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol. 2008 Jul;10(7):788-801.
64. Sorrentino A, Ferracin M, Castelli G, Biffoni M, Tomaselli G, Baiocchi M, Fatica A, Negrini M, Peschle C, Valtieri M. Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Exp Hematol. 2008 Aug;36(8):1035-46.
65. Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A, Biffoni M, Felli N, Mattia G, Petrini M, Colombo MP, Peschle C, Carè A. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res. 2008 Apr 15;68(8):2745-54.
66. Napoletano C, Taurino F, Biffoni M, De Majo A, Coscarella G, Bellati F, Rahimi H, Pauselli S, Pellicciotta I, Burchell JM, Gaspari LA, Ercoli L, Rossi P, Rughetti A. RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. Int J Oncol. 2008 Feb;32(2):481-90. PubMed PMID: 18202772.4
67. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008 Mar;15(3):504-14. Epub 2007 Nov 30. PubMed PMID: 18049477.4
68. Casorelli I, Pelosi E, Biffoni M, Cerio AM, Peschle C, Testa U, Bignami M. Methylation damage response in hematopoietic progenitor cells. DNA Repair (Amst). 2007 Aug 1;6(8):1170-8.
69. Calzolari A, Oliviero I, Deaglio S, Mariani G, Biffoni M, Sposi NM, Malavasi F, Peschle C, Testa U. Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol Dis. 2007 Jul–Aug;39(1):82-91.
70. Petrucci E, Pasquini L, Petronelli A, Saulle E, Mariani G, Riccioni R, Biffoni M, Ferretti G, Benedetti-Panici P, Cognetti F, Scambia G, Humphreys R, Peschle C, Testa U. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol Oncol. 2007 May;105(2):481-92.
71. Saulle E, Petronelli A, Pasquini L, Petrucci E, Mariani G, Biffoni M, Ferretti G, Scambia G, Benedetti-Panici P, Cognetti F, Humphreys R, Peschle C, Testa U. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis. 2007 Apr;12(4):635-55.
72. Ricci-Vitiani L, Lombardi DG, Signore M, Biffoni M, Pallini R, Parati E, Peschle C, De Maria R. Human neural progenitor cells display limited cytotoxicity and increased oligodendrogenesis during inflammation. Cell Death Differ. 2007 Apr;14(4):876-8. Epub 2006 Dec 22.
73. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007 Jan 4;445(7123):111-5.
74. Riccioni R, Calzolari A, Biffoni M, Senese M, Riti V, Petrucci E, Pasquini L, Cedrone M, Lo-Coco F, Diverio D, Foà R, Peschle C, Testa U. Podocalyxin is expressed in normal and leukemic monocytes. Blood Cells Mol Dis. 2006 Nov–Dec;37(3):218-25. Epub 2006 Oct 23. PubMed PMID: 17059890.5
75. Felli N, Pedini F, Zeuner A, Petrucci E, Testa U, Conticello C, Biffoni M, Di Cataldo A, Winkles JA, Peschle C, De Maria R. Multiple members of the TNF superfamily contribute to IFN-gamma-mediated inhibition of erythropoiesis. J Immunol. 2005 Aug 1;175(3):1464-72. PubMed PMID: 16034083.5
76. Rughetti A, Pellicciotta I, Biffoni M, Bäckström M, Link T, Bennet EP, Clausen H, Noll T, Hansson GC, Burchell JM, Frati L, Taylor-Papadimitriou J, Nuti M. Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J Immunol. 2005 Jun 15;174(12):7764-72. PubMed PMID: 15944279.6
77. Testa U, Riccioni R, Biffoni M, Diverio D, Lo-Coco F, Foà R, Peschle C, Frankel AE. Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood. 2005 Oct 1;106(7):2527-9. Epub 2005 May 31. PubMed PMID: 15928038; PubMed Central PMCID: PMC1895267.6
78. Coluzzi S, Biffoni M, Pasqualetti D, Perrone MP, Vaglio S, Rahimi H, Arista MC, Laurenti L, Cerretti R, Girelli G. Production of interferon-gamma by lymphocytes from paroxysmal nocturnal haemoglobinuria patients: relationship with clinical status. Br J Haematol. 2004 Mar;124(5):685-90. PubMed PMID: 14871257.6
79. Mastrangeli R, Donini S, Kelton CA, He C, Bressan A, Milazzo F, Ciolli V, Borrelli F, Martelli F, Biffoni M, Serlupi-Crescenzi O, Serani S, Micangeli E, El Tayar N, Vaccaro R, Renda T, Lisciani R, Rossi M, Papoian R. ARS Component B: structural characterization, tissue expression and regulation of the gene and protein (SLURP-1) associated with Mal de Meleda. Eur J Dermatol. 2003 Nov–Dec;13(6):560-70. PubMed PMID: 14721776.6
80. Pasqualetti D, Ghirardini A, Cafolla A, Biffoni M, Coluzzi S, Vaglio S, Girelli G. Lymphocyte T subsets and natural killer cells in Italian and Philippino blood donors. Vox Sang. 2003 Jan;84(1):68-72. PubMed PMID: 12542736.7
81. Rughetti A, Biffoni M, Pierelli L, Rahimi H, Bonanno G, Barachini S, Pellicciotta I, Napoletano C, Pescarmona E, Del Nero A, Pignoloni P, Frati L, Nuti M. Regulated expression of MUC1 epithelial antigen in erythropoiesis. Br J Haematol. 2003 Jan;120(2):344-52. PubMed PMID: 12542497.7
82. Rughetti A, Biffoni M, Sabbatucci M, Rahimi H, Pellicciotta I, Fattorossi A, Pierelli L, Scambia G, Lavitrano M, Frati L, Nuti M. Transfected human dendritic cells to induce antitumor immunity. Gene Ther. 2000 Sep;7(17):1458-66.
83. Baiocchi M, Marcucci I, Rose-John S, Serlupi-Crescenzi O, Biffoni M. An IL-6/IL-6 soluble receptor (IL-6R) hybrid protein (H-IL-6) induces EPO-independent erythroid differentiation in human CD34(+) cells. Cytokine. 2000 Sep;12(9):1395-9. PubMed PMID: 10976001.7
84. Biffoni M, Marcucci I, Ythier A, Eshkol A. Effects of urinary gonadotrophin preparations on human in-vitro immune function. Hum Reprod. 1998 Sep;13(9):2430-4. PubMed PMID: 9806263.8
85. Abdul-Ahad AK, Galazka AR, Revel M, Biffoni M, Borden EC. Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells. Cytokines Cell Mol Ther. 1997 Mar;3(1):27-32. PubMed PMID: 9287241.9
86. Biffoni M, Battaglia A, Borrelli F, Cantelmo A, Galli G, Eshkol A. Allergenic potential of gonadotrophic preparations in experimental animals: relevance of purity. Hum Reprod. 1994 Oct;9(10):1845-8. PubMed PMID: 7844213.9
87. Biffoni M, Cantelmo A, Marcucci I, Martelli F, Suzuki H, Borrelli F, Suzuki K. General pharmacology studies on recombinant human follicle stimulating hormone. Arzneimittelforschung. 1994 Sep;44(9):1096-102. PubMed PMID: 7986251.9
88. Biffoni M, Paroli E, Carletti M, Antonilli L. Effects of beta-casomorphins and met-enkephalin on human natural killer activity. Pharmacol Res. 1992 Sep;26 Suppl 2:164-5. PubMed PMID: 1409294.9
89. Paroli E, Antonilli L, Biffoni M. A pharmacological approach to glycosaminoglycans. Drugs Exp Clin Res. 1991;17(1):9-19. Review. PubMed PMID: 1914841.10
90. Biffoni M, Paroli E. Complement in vitro inhibition by a low-sulfate chondroitin sulfate (matrix). Drugs Exp Clin Res. 1991;17(1):35-9. PubMed PMID: 1833171.10
91. Paroli M, Biffoni M, Paroli E, Grassi MC. Inhibition of human natural killer activity by naphtalene analgesics. Pharmacol Res. 1990 Sep–Oct;22 Suppl 1:27-8. PubMed PMID: 2284236.10
92. Paroli M, Balsano C, Valesini G, Biffoni M, Perrone A, Barnaba V. [In vitro effect of alpha-interferon and thymomodulin on natural killer activity in patients with AIDS-related complex]. Ann Ital Med Int. 1988 Jan–Mar;3(1):39-42. Italian. PubMed PMID: 3152836.10
Patents
WO98/23748 “Methods for preventing graft rejection in transplantation a for producing a universal gene therapy host cell using lymphocyte activation gene -3 (LAG-3)”
WO2004/039845 “Antimicrobial lipase antibodies their nucleotide and aminoacid sequences and uses thereof”
WO2014072940 (A1) “Inhibitor of integrin for the treatment or prevention of tumors”
EPO 18746713.9 – 1111 “Monoclonal antibody anti-FGFR4” (01/8/2018)